Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
Hospitalization
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Bamlanivimab  COVID-19 treatment studies for Bamlanivimab  C19 studies: Bamlanivimab  Bamlanivimab   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 bamlanivimab studies
00.250.50.7511.251.51.752+Chen (RCT)74%0.26 [0.09-0.75]hosp.5/3099/143Improvement, RR [CI]TreatmentControlGottlieb (RCT)71%0.29 [0.09-0.96]hosp./ER4/1017/52Lilly (DB RCT)92%0.08 [0.00-1.43]death0/5114/258Webb80%0.20 [0.03-1.46]death1/47957/5,536Tau​2 = 0.00; I​2 = 0.0%Early treatment76%0.24 [0.12-0.50]10/1,40077/5,98976% improvementACTIV-3/T.. (RCT)-100%2.00 [0.69-5.83]death9/1635/151Improvement, RR [CI]TreatmentControlBariola67%0.33 [0.10-1.01]death4/23412/234Tau​2 = 1.30; I​2 = 80.7%Late treatment18%0.82 [0.14-4.77]13/39717/38518% improvementLilly (RCT)57%0.43 [0.28-0.67]symp. case483 (n)482 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP57%0.43 [0.28-0.67]0/4830/48257% improvementAll studies59%0.41 [0.23-0.74]23/2,28094/6,85659% improvement7 bamlanivimab COVID-19 studiesc19ly.com Sep 26, 2021Tau​2 = 0.25; I​2 = 46.8%; Z = 3.00Effect extraction pre-specifiedFavors bamlanivimabFavors control 00.250.50.7511.251.51.752+Lilly (DB RCT)92%0.08 [0.00-1.43]0/5114/258Improvement, RR [CI]TreatmentControlWebb80%0.20 [0.03-1.46]1/47957/5,536Tau​2 = 0.00; I​2 = 0.0%Early treatment85%0.15 [0.03-0.77]1/99061/5,79485% improvementACTIV-3/T.. (RCT)-100%2.00 [0.69-5.83]9/1635/151Improvement, RR [CI]TreatmentControlBariola67%0.33 [0.10-1.01]4/23412/234Tau​2 = 1.30; I​2 = 80.7%Late treatment18%0.82 [0.14-4.77]13/39717/38518% improvementAll studies57%0.43 [0.11-1.68]14/1,38778/6,17957% improvement4 bamlanivimab COVID-19 mortality resultsc19ly.com Sep 26, 2021Tau​2 = 1.18; I​2 = 66.6%; Z = 1.21Favors bamlanivimabFavors control 00.250.50.7511.251.51.752+Chen (RCT)74%0.26 [0.09-0.75]hosp.5/3099/143Improvement, RR [CI]TreatmentControlWebb53%0.47 [0.31-0.72]hosp.22/479538/5,536Tau​2 = 0.01; I​2 = 6.7%Early treatment57%0.43 [0.28-0.66]27/788547/5,67957% improvementBariola61%0.39 [0.22-0.70]hosp.15/23439/234Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment61%0.39 [0.22-0.70]15/23439/23461% improvementAll studies58%0.42 [0.31-0.58]42/1,022586/5,91358% improvement3 bamlanivimab COVID-19 hospitalization resultsc19ly.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 5.28Favors bamlanivimabFavors control 00.250.50.7511.251.51.752+Chen (RCT)74%0.26 [0.09-0.75]hosp.5/3099/143Improvement, RR [CI]TreatmentControlGottlieb (RCT)71%0.29 [0.09-0.96]hosp./ER4/1017/52Lilly (DB RCT)92%0.08 [0.00-1.43]death0/5114/258Webb80%0.20 [0.03-1.46]death1/47957/5,536Tau​2 = 0.00; I​2 = 0.0%Early treatment76%0.24 [0.12-0.50]10/1,40077/5,98976% improvementACTIV-3/T.. (RCT)-100%2.00 [0.69-5.83]death9/1635/151Improvement, RR [CI]TreatmentControlBariola67%0.33 [0.10-1.01]death4/23412/234Tau​2 = 1.30; I​2 = 80.7%Late treatment18%0.82 [0.14-4.77]13/39717/38518% improvementAll studies62%0.38 [0.17-0.89]23/1,79794/6,37462% improvement6 bamlanivimab COVID-19 serious outcomesc19ly.com Sep 26, 2021Tau​2 = 0.57; I​2 = 55.7%; Z = 2.24Effect extraction pre-specifiedFavors bamlanivimabFavors control 00.250.50.7511.251.51.752+Chen (RCT)74%0.26 [0.09-0.75]hosp.5/3099/143Improvement, RR [CI]TreatmentControlGottlieb (RCT)71%0.29 [0.09-0.96]hosp./ER4/1017/52Lilly (DB RCT)92%0.08 [0.00-1.43]death0/5114/258Tau​2 = 0.00; I​2 = 0.0%Early treatment75%0.25 [0.12-0.54]9/92120/45375% improvementACTIV-3/T.. (RCT)-100%2.00 [0.69-5.83]death9/1635/151Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-100%2.00 [0.69-5.83]9/1635/151-100% improvementLilly (RCT)57%0.43 [0.28-0.67]symp. case483 (n)482 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP57%0.43 [0.28-0.67]0/4830/48257% improvementAll studies55%0.45 [0.21-0.97]18/1,56725/1,08655% improvement5 bamlanivimab COVID-19 Randomized Controlled Trialsc19ly.com Sep 26, 2021Tau​2 = 0.42; I​2 = 61.7%; Z = 2.05Effect extraction pre-specifiedFavors bamlanivimabFavors control 00.250.50.7511.251.51.752+Lilly (DB RCT)92%0.08 [0.00-1.43]0/5114/258Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment92%0.08 [0.00-1.43]0/5114/25892% improvementACTIV-3/T.. (RCT)-100%2.00 [0.69-5.83]9/1635/151Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-100%2.00 [0.69-5.83]9/1635/151-100% improvementAll studies47%0.53 [0.02-12.1]9/6749/40947% improvement2 bamlanivimab COVID-19 RCT mortality resultsc19ly.com Sep 26, 2021Tau​2 = 4.03; I​2 = 76.2%; Z = 0.40Favors bamlanivimabFavors control 00.250.50.7511.251.51.752+Chen (RCT)74%0.26 [0.09-0.75]hosp.5/3099/143Improvement, RR [CI]TreatmentControlGottlieb (RCT)71%0.29 [0.09-0.96]hosp./ER4/1017/52Webb80%0.20 [0.03-1.46]death1/47957/5,536Tau​2 = 0.00; I​2 = 0.0%Early treatment74%0.26 [0.13-0.55]10/88973/5,73174% improvementACTIV-3/T.. (RCT)-100%2.00 [0.69-5.83]death9/1635/151Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-100%2.00 [0.69-5.83]9/1635/151-100% improvementAll studies55%0.45 [0.15-1.40]19/1,05278/5,88255% improvement4 bamlanivimab COVID-19 peer reviewed trialsc19ly.com Sep 26, 2021Tau​2 = 0.87; I​2 = 68.4%; Z = 1.38Effect extraction pre-specifiedFavors bamlanivimabFavors control 00.250.50.7511.251.51.752+Chen (RCT)74%0.26 [0.09-0.75]hosp.5/3099/143Improvement, RR [CI]TreatmentControlGottlieb (RCT)71%0.29 [0.09-0.96]hosp./ER4/1017/52Gottlieb (RCT)80%0.20 [0.03-1.56]hosp./ER1/377/52Gottlieb (RCT)75%0.25 [0.03-1.92]hosp./ER1/307/52Gottlieb (RCT)56%0.44 [0.10-1.98]hosp./ER2/347/52Gottlieb (RCT)92%0.08 [0.00-1.39]hosp./ER0/317/52Lilly (DB RCT)92%0.08 [0.00-1.43]death0/5114/258Lilly (DB RCT)87%0.13 [0.05-0.40]hosp./death4/51115/258Webb80%0.20 [0.03-1.46]death1/47957/5,536Webb53%0.47 [0.31-0.72]hosp.22/479538/5,536ACTIV-3/T.. (RCT)-100%2.00 [0.69-5.83]death9/1635/151Bariola67%0.33 [0.10-1.01]death4/23412/234Bariola61%0.39 [0.22-0.70]hosp.15/23439/234Lilly (RCT)57%0.43 [0.28-0.67]symp. case483 (n)482 (n)Lilly (RCT)80%0.20 [0.08-0.47]symp. case150 (n)149 (n)bamlanivimab COVID-19 outcomesc19ly.com Sep 26, 2021Favors bamlanivimabFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit